Given that our data suggest that PTEN-wt prostate cancer cell lines rely on mGluR1 and HER2 to overcome PI3K/mTOR inhibition, we sought to evaluate whether simultaneous inhibition of both signaling pathways would impact on the tumorigenic potential of these cell lines. Here, GRM1 is linked to prostate cancer.